1Lastres-Becker I, Fernandez-Ruiz J. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments [ J ]. Curr Med Chem,2006,13 (30) :3705-3718.
2Ryberg E, Vu HK, Larsson N, et al. Identification and characterisation of a novel splice variant of the human CB1 receptor[J]. FEBS Lett, 2005,579( 1 ) :259-264.
3Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids [ J ]. Proc Natl Acad Sci,2005,102 ( 18 ) : 17852-17857.
4Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models [J]. Nature, 2007,445 (7128) :643-647.
5Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum [ J ]. Neumsci ,2005,25 (16) : 10537-10545.
6Andersson M, Usiello A, Borgkvist A, et al. Cannabinoid action depends on phosphorylation of dopamine-and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons [ J ]. Neurosci,2005,16 ( 8 ) : 8432-8438.
7Maccarrone M, Battista N, Centonze D. The endocannabinoid pathway in Huntington'ss disease: a comparison with other neurodegenerative diseases [ J ]. Prog Neurobiol,2007,81 (56) :349-379.
8Eljaschewitsch E, Witting A, Schmidt P, et al. The endocannabinoid anadamide (AEA) protects neurons during CNS inflammation by induction of MKP-1 in microglial cells[ J]. Neuron,2006,49( 15 ) :67- 79.
9Ullrich O, Merker K, Timm J. Immune control by endocannabinoidsnew mechanisms of neuroprotection [ J ]. Neuroimmunol, 2007, 184 ( 1 ) : 127-135.
10Sipe JC, Arbour N, Gerber A, et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 ( CB2 ) receptor gene polymorphism: possible risk for autoimmune disorders [ J ]. Leukoc Biol,2005,78 ( 17 ) :231-238.
4Lastres - Becker I, Fernandez - Ruiz J. An overview of Parkinson: disease and the eannabinoid system and pos- sible benefits of cannabinoid - based treatments[J ].Curr Med Chem, 2006, 13 (30) : 3705 -3718.
5Fride E. Endocannabinoids in the central nervous sys- tem- an overview [ J ]. Prostaglandins Leukot EssentFatty Acids, 2002, 66 (2): 221-233.
6Ryberg E, V u HK, Larsson N, et al. Identification and characterisation of a novel splice variant of the hu- man CB1 receptor [J]. FEBS Lett, 2005, 579 (1) : 259 - 264.
7Yoshinobu K, Masahiro F, Takashi M, et al. The CB1 cannabinoid receptor is the major cannabinoid re- ceptor at excitatory presynaptic sites in the hippocampus and cerebellum [J]. J Neurosci, 2006, 26 (11): 2991 - 3001.
8Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function [ J ]. Bio- chem Biophys Res Commun, 1999, 256 (2) : 377 - 380.
9Ullrich O, Merker K, Timm J, et al. Immune control by endocannabinoids - new mechanisms of neuroprotec- tion [J]. Neuroimmunol, 2007, 184 (1): 127 -135.
10Kim SR, Lee da Y, Chung ES, et al. Transient re- ceptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro [J]. Neurosci, 2005, 25 (3): 662-671.
